openPR Logo
Press release

IgG4-related Disease Market to Register Incremental Growth During the Forecast Period (2024-2034), Asserts DelveInsight | Zenas BioPharma, Horizon Therapeutics, Amgen, Sanofi, UMC Utrecht

05-24-2024 08:09 PM CET | Health & Medicine

Press release from: DelveInsight Business Research

IgG4-related Disease Market to Register Incremental Growth

DelveInsight's "IgG4-related Disease Market Insights, Epidemiology, and Market Forecast-2034″ report offers an in-depth understanding of the IgG4-related Disease, historical and forecasted epidemiology as well as the IgG4-related Disease market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.

To Know in detail about the IgG4-related Disease market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; IgG4-related Disease Market Forecast
https://www.delveinsight.com/sample-request/igg4-related-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Some of the key facts of the IgG4-related Disease Market Report:
• The IgG4-related Disease market size was valued approximately 150 million in 2023 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
• The United States held the largest market size for IgG4-related disease treatment, approximately USD 115 million, compared to EU4 (Germany, Spain, Italy, France), the United Kingdom, and Japan.
• Only a few treatments are under scrutiny for IgG4 related disease management. Prominent developers include Zenas Biopharma with obexelimab, Amgen/Horizon Therapeutics with inebilizumab, and Sanofi with rilzabrutinib.
• In 2023, the 7MM collectively had an estimated 300,000 existing cases of IgG4-related disease.
• According to the findings, IgG4-related disease was more prevalent among males in the 7MM.
• According to DelveInsight's estimates, there were approximately 60,000 diagnosed prevalent cases of IgG4-related disease in the United States in 2023.
• In 2023, among the EU4 countries and the UK, Germany had the highest total prevalent population of IgG4-related disease patients with 27,000 cases, followed by France and the UK.
• ZB012 (obexelimab) and UPLIZNA (inebilizumab) are anticipated to secure a substantial market share in the projected period.
• Key IgG4-related Disease Companies: Zenas BioPharma, Horizon Therapeutics, Amgen, Sanofi, UMC Utrecht, and others
• Key IgG4-related Disease Therapies: ZB012 (obexelimab), UPLIZNA (inebilizumab), rilzabrutinib, Filgotinib, and others
• The IgG4-related Disease market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage IgG4-related Disease pipeline products will significantly revolutionize the IgG4-related Disease market dynamics.

IgG4-related Disease Overview
IgG4-related disease (IgG4-RD) is a rare immune-mediated condition characterized by the infiltration of various organs with IgG4-positive plasma cells, leading to inflammation, fibrosis, and tissue damage. It can affect multiple organs simultaneously or sequentially, including the pancreas, salivary glands, lacrimal glands, kidneys, lungs, and lymph nodes.

Get a Free sample for the IgG4-related Disease Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/igg4-related-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

IgG4-related Disease Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

IgG4-related Disease Epidemiology Segmentation:
The IgG4-related Disease market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
• Total Prevalence of IgG4-related Disease
• Prevalent Cases of IgG4-related Disease by severity
• Gender-specific Prevalence of IgG4-related Disease
• Diagnosed Cases of Episodic and Chronic IgG4-related Disease

Download the report to understand which factors are driving IgG4-related Disease epidemiology trends @ IgG4-related Disease Epidemiology Forecast
https://www.delveinsight.com/sample-request/igg4-related-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

IgG4-related Disease Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the IgG4-related Disease market or expected to get launched during the study period. The analysis covers IgG4-related Disease market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the IgG4-related Disease Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

IgG4-related Disease Therapies and Key Companies
• ZB012 (obexelimab): Zenas BioPharma
• UPLIZNA (inebilizumab): Horizon Therapeutics/Amgen
• rilzabrutinib: Sanofi
• Filgotinib: UMC Utrecht

Discover more about therapies set to grab major IgG4-related Disease market share @ IgG4-related Disease Treatment Landscape
https://www.delveinsight.com/sample-request/igg4-related-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Scope of the IgG4-related Disease Market Report
• Study Period: 2020-2034
• Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
• Key IgG4-related Disease Companies: Zenas BioPharma, Horizon Therapeutics, Amgen, Sanofi, UMC Utrecht, and others
• Key IgG4-related Disease Therapies: ZB012 (obexelimab), UPLIZNA (inebilizumab), rilzabrutinib, Filgotinib, and others
• IgG4-related Disease Therapeutic Assessment: IgG4-related Disease current marketed and IgG4-related Disease emerging therapies
• IgG4-related Disease Market Dynamics: IgG4-related Disease market drivers and IgG4-related Disease market barriers
• Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
• IgG4-related Disease Unmet Needs, KOL's views, Analyst's views, IgG4-related Disease Market Access and Reimbursement

To know more about IgG4-related Disease companies working in the treatment market, visit @ IgG4-related Disease Clinical Trials and Therapeutic Assessment
https://www.delveinsight.com/sample-request/igg4-related-disease-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr

Table of Contents
1. IgG4-related Disease Market Report Introduction
2. Executive Summary for IgG4-related Disease
3. SWOT analysis of IgG4-related Disease
4. IgG4-related Disease Patient Share (%) Overview at a Glance
5. IgG4-related Disease Market Overview at a Glance
6. IgG4-related Disease Disease Background and Overview
7. IgG4-related Disease Epidemiology and Patient Population
8. Country-Specific Patient Population of IgG4-related Disease
9. IgG4-related Disease Current Treatment and Medical Practices
10. IgG4-related Disease Unmet Needs
11. IgG4-related Disease Emerging Therapies
12. IgG4-related Disease Market Outlook
13. Country-Wise IgG4-related Disease Market Analysis (2020--2034)
14. IgG4-related Disease Market Access and Reimbursement of Therapies
15. IgG4-related Disease Market Drivers
16. IgG4-related Disease Market Barriers
17. IgG4-related Disease Appendix
18. IgG4-related Disease Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight

Related Reports:

IgG4-related Disease Pipeline https://www.delveinsight.com/report-store/igg4-related-disease-pipeline-insight?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
"IgG4-related Disease Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights of present clinical development scenarios and growth prospects across the IgG4-related Disease market. A detailed picture of the IgG4-related Disease pipeline landscape is provided, which includes the disease overview and IgG4-related Disease treatment guidelines.

IgG4-related Disease Epidemiology https://www.delveinsight.com/report-store/igg4-related-disease-epidemiology-forecast?utm_source=openpr&utm_medium=pressrelease&utm_campaign=gpr
DelveInsight's 'IgG4-related Disease Epidemiology Forecast to 2032' report delivers an in-depth understanding of the disease, historical and forecasted IgG4-related Disease epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Latest Reports by DelveInsight

Crows Feet Market
https://www.delveinsight.com/report-store/crows-feet-market
DelveInsight's "Crows Feet Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Crows Feet, historical and forecasted epidemiology as well as the Crows Feet market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Dermatitis Seborrheic Market https://www.delveinsight.com/report-store/seborrhoeic-dermatitis-market
DelveInsight's "Seborrhoeic Dermatitis Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Seborrhoeic Dermatitis, historical and forecasted epidemiology as well as the Seborrhoeic Dermatitis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Gastro Intestinal Bleeding Market https://www.delveinsight.com/report-store/gastro-intestinal-bleeding-market
DelveInsight's "Gastro Intestinal Bleeding Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Gastro Intestinal Bleeding, historical and forecasted epidemiology as well as the Gastro Intestinal Bleeding market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Listeriosis Market
https://www.delveinsight.com/report-store/listeriosis-market
DelveInsight's comprehensive report titled "Listeriosis Market Insights, Epidemiology, and Market Forecast - 2034" offers a detailed analysis of Listeriosis. The report presents historical and projected epidemiological data covering incident cases of listeriosis, age-specific cases of listeriosis, gender-specific cases of listeriosis, risk-associated cases of listeriosis, and treated cases of listeriosis.

Point Of Care Glucose Testing Market https://www.delveinsight.com/report-store/point-of-care-glucose-testing-market
DelveInsight's 'Point of Care Glucose Testing Market Insight, Competitive Landscape and Market Forecast, 2030' report delivers an in-depth understanding of Point of Care Glucose Testing and the historical and forecasted Point of Care Glucose Testing market trends, globally, which comprises of North America, Europe, APAC, and RoW.

Substance Drug Abuse Market https://www.delveinsight.com/report-store/substance-drug-abuse-market
DelveInsight's "Substance (Drug) Abuse Market Insights, Epidemiology, and Market Forecast-2032" report delivers an in-depth understanding of the Substance (Drug) Abuse, historical and forecasted epidemiology as well as the Substance (Drug) Abuse market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Gaurav Bora
Email: info@delveinsight.com
Contact No.: +14699457679
City: 304 S. Jones Blvd #2432, Las Vegas
State: Nevada (89107)
Country: United States
Website: https://www.delveinsight.com/consulting

About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release IgG4-related Disease Market to Register Incremental Growth During the Forecast Period (2024-2034), Asserts DelveInsight | Zenas BioPharma, Horizon Therapeutics, Amgen, Sanofi, UMC Utrecht here

News-ID: 3512185 • Views:

More Releases from DelveInsight Business Research

Anaplastic Thyroid Cancer Pipeline Dynamics 2024: FDA Approvals, Therapeutic Advances, and Clinical Trials Insights | Johnson and Johnson, Medtronic Plc, Merck KGaA, Novartis AG, Pfizer Inc., Akorn Inc., Amneal Pharmaceuticals Inc.
Anaplastic Thyroid Cancer Pipeline Dynamics 2024: FDA Approvals, Therapeutic Adv …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Anaplastic Thyroid Cancer pipeline constitutes 8+ key companies continuously working towards developing 8+ Anaplastic Thyroid Cancer treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. "Anaplastic Thyroid Cancer Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across the Anaplastic Thyroid
Parkinson's Disease Psychosis Clinical Trials Analysis 2024: EMA, PDMA, FDA Approvals, Treatment Market, Therapies, ROA, MOA and Key Companies by DelveInsight | Vanda Pharmaceuticals, Sumitomo Pharma, ACADIA Pharmaceuticals, Otsuka America Pharmaceutical,
Parkinson's Disease Psychosis Clinical Trials Analysis 2024: EMA, PDMA, FDA Appr …
(Albany, United States) As per DelveInsight's assessment, globally, the Parkinson's disease Psychosis Pipeline constitutes 5+ key companies continuously working towards developing 5+ Parkinson's Disease Psychosis Pipeline treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analysis DelveInsight. In the Parkinson's Disease Psychosis pipeline report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any),
Relapsed/Refractory Acute Myeloid Leukemia Pipeline 2024: Clinical Trials Assessment, FDA Approvals, Therapies, and Key Companies Involved by DelveInsight | Foghorn Therapeutics, AB Science, Oncoceutics, Sanofi, TC Biopharm, Merck & Co, GlycoMimetics
Relapsed/Refractory Acute Myeloid Leukemia Pipeline 2024: Clinical Trials Assess …
(Las Vegas, Nevada, United States) As per DelveInsight's assessment, globally, Relapsed/Refractory Acute Myeloid Leukemia pipeline constitutes 50+ key companies continuously working towards developing 50+ Relapsed/Refractory Acute Myeloid Leukemia treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analyzes DelveInsight. "Relapsed/Refractory Acute Myeloid Leukemia Pipeline Insight, 2024" report by DelveInsight outlines comprehensive insights into the present clinical development scenario and growth prospects across
Oral Mucositis Clinical Trials Analysis 2024: EMA, PDMA, FDA Approvals, Pipeline, Therapies, Mechanism of Action, Route of Administration and Companies by DelveInsight
Oral Mucositis Clinical Trials Analysis 2024: EMA, PDMA, FDA Approvals, Pipeline …
(Albany, United States) As per DelveInsight's assessment, globally, the Oral Mucositis Pipeline constitutes 10+ key companies continuously working towards developing 10+ Oral Mucositis Pipeline treatment therapies, analysis of Clinical Trials, Therapies, Mechanism of Action, Route of Administration, and Developments analysis DelveInsight. In the Oral Mucositis Pipeline Report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, Oral Mucositis NDA approvals (if any), and

All 5 Releases


More Releases for IgG4

IgG4-Related Disease Market to Observe Stupendous Growth During the Forecast Per …
DelveInsight's "IgG4-Related Disease Market Insights, Epidemiology, and Market Forecast 2032" report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the IgG4-Related Disease Market Size and Share in the 7MM (i.e., the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan). The IgG4-Related Disease market report covers emerging drugs, treatment practices, market share of the individual therapies, and current & forecasted market size
Chidamide Market Revenue, Industry Growing Demand, Top Companies, Regional Outlo …
The global chidamide market is anticipated to grow at a CAGR of 3.2% during the forecast period (2022-2028). The increasing prevalence of cancer globally is a major driving factor for the chidamide industry growth. Furthermore, the market is likely to be driven by continuing clinical trials for chidamide and an increased need for new treatment choices over the forecast period. Rising rates of cancers such as ovarian cancer, breast cancer,
Global IgG4-Related Disease Market Analysis, Leading Players, Future Growth, Bus …
The scope of an excellent IgG4-Related Disease Market report can be expanded from market scenarios to comparative pricing between major players. This market analysis examines various segments which help for the quickest development amid the estimated forecast frame. Moreover, estimation of strategic options, suggestions of winning action plans and support to make critical bottom-line decisions is also provided by experienced and innovative industry experts. This global market analysis report contains
IgG4-Related Disease Market Potential Growth, Share, Demand and Analysis Of Key …
According to the persuasive IgG4-Related Disease Market report, the leading players are focusing more on offering products at rational prices to gain a competitive advantage over the other players in the industry. Moreover, the report aims to examine the overall size of the market and infer the key from it. To inspect the market based on market share, product, and product share. It also evaluates the market on
IgG4-Related Disease Market Increasing Investment is Expected To Boost Industry …
The universal IgG4-Related Disease Market report offers a meticulous investigation of the current scenario of the global market, which considers numerous market dynamics. The report identifies and analyses the emerging trends along with key drivers, challenges, and opportunities in the industry. This market document comprises of historic data, present market trends, market environment, technological innovation, upcoming technologies, and the technical progress in the related industry. The data and information about
Increasing awareness of new treatment of early diagnosis to bring profitable opp …
In myelodysplastic syndrome (MDS), some of the cells from bone marrow are abnormal and have problems making new blood cells. Moreover, increasing possibility of MDS to further progress into rapidly growing cancer of bone marrow cells called acute myeloid leukemia (AML), leads to increasing efforts by key players develop highly effective therapies for MDS treatment. Manufacturers across the globe have been receiving regulatory approvals for the development and launch of